MitoKIN

From Bioblast
Jump to navigation Jump to search



MitoKIN

MitoKIN - Systematic barcoding of kinase-controlled mitochondrial function

FFG


MitoKIN: FFG BRIDGE 1

  • FFG BRIDGE 1 30. Call - Project No. 877163, University of Innsbruck, Institute of Biochemistry
  • Duration: 36 months
  • Start: 2020-02-03


Dr. Eduard Stefan and Dr. Omar Torres-Quesada receiving the O2k instruments for the MitoKIN project.

About MitoKIN

Led by the Institute of Biochemistry at the University of Innsbruck, the MitoKIN project aims to connect specific/broad kinase activities to precise metabolic functions (mitochondria) relevant for cell proliferation or survival. Applied inhibitors could then be used to barcode involved kinase pathways that change the metabolome by boosting or preventing mitochondrial functions.

Aims

The MitoKIN project has three major aims:
1. Impact of specific/general kinase inhibition on metabolism & mitochondrial function.
2. Perturbation of PKA signaling in cancer cells (high cAMP levels).
3. Perturbation of PKA signaling in neurodegenerative disease models (low cAMP levels).


Coordinator


Network

Back row, left to right: Eduard, Verana, Carolina, Erich; front row left to right: Lisa, Omar

Participants

Institute of Biochemistry, University of Innsbruck
Oroboros Instruments GmbH - www.oroboros.at



Oroboros project involvement

Oroboros Instruments will provide both infrastructure and the expertise required to conduct the respirometric measurements of the project.
The Institute of Biochemistry has been equipped with 3 O2ks for the duration of the project.

MitoKIN publications, preprints, abstracts and events

 WhenWhere
MiPNet25.06 IOC145 Innsbruck AT2020-01-27
OROBOROS-solo.png
Innsbruck AT, 2020 Jan 27-29. O2k-Coaching Days - Basic IOC145.
Torres-Quesada 2022 Cancers (Basel)2022Torres-Quesada O, Doerrier C, Strich S, Gnaiger E, Stefan E (2022) Physiological cell culture media tune mitochondrial bioenergetics and drug sensitivity in cancer cell models. https://doi.org/10.3390/cancers14163917
Torres-Quesada 2022 MitoFit2022-04-01Torres-Quesada O, Doerrier C, Strich S, Gnaiger E, Stefan E (2022) Human Plasma-Like Media fine-tune mitochondrial function and alter drug sensitivity in cancer cell lines. https://doi.org/10.26124/mitofit:2022-0008 - 2022-08-13 published in https://doi.org/10.3390/cancers14163917
Torres-Quesada 2022 MitoFit Kinase2022-04-11Torres-Quesada O, Strich S, Stefan E (2022) Kinase perturbations redirect mitochondrial function. https://doi.org/10.26124/mitofit:2022-0011


Links

News and articles

#SuccessStory: KinCon lässt Medikamenten-Forschung aufleuchten www.ffg.at, 2022-08-08
Krebs, Kinasen und Zellkraft­werke www.uibk.ac.at, 2020-02-04


Support

This project has received funding from the Austrian Reserach Promotion Funding Agency (FFG).

FFG-logo.png